Kah Poh Loh1, Vivian Lam2, Katey Webber3, Simran Padam4, Mina S Sedrak4, Vivek Musinipally5, Madison Grogan6, Carolyn J Presley6, Janice Grandi2, Chandrika Sanapala1, Daniel A Castillo7, Grace DiGiovanni1, Supriya G Mohile1, Louise C Walter8,9, Melisa L Wong2,8,9. 1. 1Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York. 2. 2Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California. 3. 3School of Public Health, University of California, Berkeley, Berkeley, California. 4. 4Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California. 5. 5Department of Adult and Family Medicine, Kaiser Permanente, San Francisco, California. 6. 6Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio. 7. 7Edward G. Miner Library, University of Rochester School of Medicine and Dentistry, Rochester, New York; and. 8. 8Division of Geriatrics, University of California, San Francisco, and. 9. 9San Francisco Veterans Affairs Medical Center, San Francisco, California.
Abstract
BACKGROUND: Maintaining functional status is important to older adults with cancer, but data are limited on how systemic treatments affect functional status. We systematically reviewed changes in functional status during systemic cancer treatments and identified characteristics associated with functional decline and improvement. METHODS: We searched PubMed, Embase, Web of Science, and Cochrane Register of Controlled Trials for articles examining characteristics associated with functional changes in older adults during systemic cancer treatment published in English between database inception and January 11, 2019 (PROSPERO CRD42019123125). Findings were summarized with descriptive statistics. Study characteristics between older adult-specific and non-older adult-specific studies were compared using the Fisher exact test. RESULTS: We screened 15,244 titles/abstracts and 519 full texts. The final analysis included 44 studies, which enrolled >8,400 patients; 39% of studies focused on older adults (1 study enrolled adults aged ≥60 years, 10 enrolled adults aged ≥65 years, and 6 enrolled adults aged ≥70 years). Almost all studies (98%) used patient-reported outcomes to measure functional status; only 20% used physical performance tests. Reporting of functional change was heterogeneous, with 48% reporting change scores. Older adult-specific studies were more likely to analyze functional change dichotomously (29% vs 4%; P=.008). Functional decline ranged widely, from 6% to 90%. The most common patient characteristics associated with functional decline were older age (n=7 studies), worse performance status (n=4), progressive disease status (n=4), pain (n=4), anemia (n=4), and worse nutritional status (n=4). Twelve studies examined functional improvement and identified 11 unique associated characteristics. CONCLUSIONS: Functional decline is increasingly recognized as an important outcome in older adults with cancer, but definitions and analyses are heterogeneous, leading to a wide range of prevalence. To identify patients at highest risk of functional decline during systemic cancer treatments, trials need to routinely analyze functional outcomes and measure characteristics associated with decline (eg, nutrition).
BACKGROUND: Maintaining functional status is important to older adults with cancer, but data are limited on how systemic treatments affect functional status. We systematically reviewed changes in functional status during systemic cancer treatments and identified characteristics associated with functional decline and improvement. METHODS: We searched PubMed, Embase, Web of Science, and Cochrane Register of Controlled Trials for articles examining characteristics associated with functional changes in older adults during systemic cancer treatment published in English between database inception and January 11, 2019 (PROSPERO CRD42019123125). Findings were summarized with descriptive statistics. Study characteristics between older adult-specific and non-older adult-specific studies were compared using the Fisher exact test. RESULTS: We screened 15,244 titles/abstracts and 519 full texts. The final analysis included 44 studies, which enrolled >8,400 patients; 39% of studies focused on older adults (1 study enrolled adults aged ≥60 years, 10 enrolled adults aged ≥65 years, and 6 enrolled adults aged ≥70 years). Almost all studies (98%) used patient-reported outcomes to measure functional status; only 20% used physical performance tests. Reporting of functional change was heterogeneous, with 48% reporting change scores. Older adult-specific studies were more likely to analyze functional change dichotomously (29% vs 4%; P=.008). Functional decline ranged widely, from 6% to 90%. The most common patient characteristics associated with functional decline were older age (n=7 studies), worse performance status (n=4), progressive disease status (n=4), pain (n=4), anemia (n=4), and worse nutritional status (n=4). Twelve studies examined functional improvement and identified 11 unique associated characteristics. CONCLUSIONS: Functional decline is increasingly recognized as an important outcome in older adults with cancer, but definitions and analyses are heterogeneous, leading to a wide range of prevalence. To identify patients at highest risk of functional decline during systemic cancer treatments, trials need to routinely analyze functional outcomes and measure characteristics associated with decline (eg, nutrition).
Authors: Ethan Basch; Bryce B Reeve; Sandra A Mitchell; Steven B Clauser; Lori M Minasian; Amylou C Dueck; Tito R Mendoza; Jennifer Hay; Thomas M Atkinson; Amy P Abernethy; Deborah W Bruner; Charles S Cleeland; Jeff A Sloan; Ram Chilukuri; Paul Baumgartner; Andrea Denicoff; Diane St Germain; Ann M O'Mara; Alice Chen; Joseph Kelaghan; Antonia V Bennett; Laura Sit; Lauren Rogak; Allison Barz; Diane B Paul; Deborah Schrag Journal: J Natl Cancer Inst Date: 2014-09-29 Impact factor: 13.506
Authors: Clark DuMontier; Michael A Liu; Anays Murillo; Tammy Hshieh; Houman Javedan; Robert Soiffer; Richard M Stone; Jane A Driver; Gregory A Abel Journal: J Am Geriatr Soc Date: 2019-04-04 Impact factor: 5.562
Authors: Marie-Rose B S Crombag; Aurelia H M de Vries Schultink; Jacobine G C van Doremalen; Hans-Martin Otten; Andries M Bergman; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema Journal: Drugs Aging Date: 2019-04 Impact factor: 3.923
Authors: Timothy J Williamson; Alyssa K Choi; Julie C Kim; Edward B Garon; Jenessa R Shapiro; Michael R Irwin; Jonathan W Goldman; Krikor Bornyazan; James M Carroll; Annette L Stanton Journal: J Thorac Oncol Date: 2018-07-05 Impact factor: 15.609
Authors: Heidi D Klepin; Janet A Tooze; Timothy S Pardee; Leslie R Ellis; Dmitriy Berenzon; Shannon L Mihalko; Suzanne C Danhauer; Arati V Rao; Tanya M Wildes; Jeff D Williamson; Bayard L Powell; Stephen B Kritchevsky Journal: J Am Geriatr Soc Date: 2016-09-14 Impact factor: 5.562
Authors: Ajeet Gajra; Linda McCall; Hyman B Muss; Harvey J Cohen; Aminah Jatoi; Karla V Ballman; Ann H Partridge; Linda Sutton; Barbara A Parker; Gustav Magrinat; Heidi D Klepin; Jacqueline M Lafky; Arti Hurria Journal: J Geriatr Oncol Date: 2018-03-28 Impact factor: 3.599
Authors: Melisa L Wong; Ying Shi; Alexander K Smith; Christine Miaskowski; W John Boscardin; Harvey Jay Cohen; Vivian Lam; Melissa Mazor; Lia Metzger; Carolyn J Presley; Grant R Williams; Kah Poh Loh; Carling J Ursem; Terence W Friedlander; Collin M Blakely; Matthew A Gubens; Gregory Allen; Dianne Shumay; Louise C Walter Journal: J Am Geriatr Soc Date: 2021-10-05 Impact factor: 5.562
Authors: Melisa L Wong; Francesca M Nicosia; Alexander K Smith; Louise C Walter; Vivian Lam; Harvey Jay Cohen; Kah Poh Loh; Supriya G Mohile; Carling J Ursem; Margaret L Schwarze Journal: J Geriatr Oncol Date: 2022-02-02 Impact factor: 3.929
Authors: Eni Shehu; Sigrid Roggendorf; André Golla; Antonia Koenig; Gabriele I Stangl; Andrea Diestelhorst; Daniel Medenwald; Dirk Vordermark; Anke Steckelberg; Heike Schmidt Journal: Cancers (Basel) Date: 2022-05-24 Impact factor: 6.575
Authors: Carolyn J Presley; Nicole A Arrato; Peter G Shields; David P Carbone; Melisa L Wong; Jason Benedict; Sarah A Reisinger; Ling Han; Thomas M Gill; Heather Allore; Barbara L Andersen; Sarah Janse Journal: JTO Clin Res Rep Date: 2022-05-17
Authors: Carolyn J Presley; Nicole A Arrato; Sarah Janse; Peter G Shields; David P Carbone; Melisa L Wong; Ling Han; Thomas M Gill; Heather G Allore; Barbara L Andersen Journal: JCO Oncol Pract Date: 2021-05-03
Authors: Lindsay C Kobayashi; Ashly C Westrick; Aalap Doshi; Katrina R Ellis; Carly R Jones; Elizabeth LaPensee; Alison M Mondul; Megan A Mullins; Lauren P Wallner Journal: Cancer Date: 2022-02-23 Impact factor: 6.921